Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Fully Immersive 3D AR Surgical Navigation System Demonstrates High Accuracy for EVD Placement

By HospiMedica International staff writers
Posted on 23 Jan 2023

External ventricular drain (EVD) is a common neurosurgical procedure, although it hasn't changed significantly in 100 years. More...

Bedside ICU ventriculostomy is a common procedure that is fraught with error, and placement errors occur in about 40% of cases using the standard freehand technique. Now, an augmented reality surgical navigation system has demonstrated its potential to improve the accuracy of EVD placement.

Researchers evaluated VisAR, a low-cost navigation technology from Novarad Corporation (Provo, UT, USA) that uses an off-the-shelf Microsoft AR headset to revolutionize the delivery of neurosurgical care. With under two-minute setup time, image visible codes for instant registration, and a preoperative planning system allowing trajectory and target design, Novarad's VisAR system improves workflow while reducing costs compared to other navigation technologies.

For their study, the researchers constructed phantom models: a skull phantom model filled with ballistic gelatin and a phantom model simulating the ventricular structure. In addition, the ability of VisAR flattening the learning curve and improving the accuracy of surgeons of various levels of training was studied in a cadaver model. The measured accuracy was done using VisAR on both phantom and cadaver models. The researchers found that the efficacy of Novarad's VisAR augmented reality guidance system demonstrated an angular error of 1.3° (close to what can be achieved with a robot and below the 2° standard for stereotactic cranial navigation set by the FDA. This result is dramatically better than current standard of care freehand technique. The various experience levels of the participants did not impact their success, illustrating the potential of VisAR accelerating the training of physicians.

"VisAR provides the precision of a robot, the portability of a stethoscope, and the versatility of human-powered intelligence," said Dr. Wendell Gibby, Founder and CEO, Novarad.

"Overall, these accuracy results suggest that a surgeon placing an EVD with AR technology would be capable of millimeter accuracy, which could be especially helpful in cases with small or displaced ventricles," said Dr. Michael Karsy, Assistant Professor of Neurosurgery, Neurooncology, and Skull Base, University of Utah Health.

Related Links:
Novarad Corporation


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.